SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Surya Pharmaceutical recommends dividend

16 Aug 2011 Evaluate

Surya Pharmaceutical has informed that the board of directors of the company at its meeting held on August 13, 2011, recommended a dividend at the rate of 15% (Re 0.15 per share) on equity shares of Rs 1 each for the financial year 2010-11.

Further the company has informed that M. L. Sharma has resigned from the directorship of the company with effect from July 23, 2011. The board has appointed R. K. Gupta as independent additional director of the company with immediate effect and the board of directors of the company has decided to mobilize funds through fixed Deposits.

The above information is part of the company's filing submitted to the BSE.

Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×